Mucosan Multi-Symptom Cherry

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the relief of symptoms associated with colds, specifically nasal congestion and cough due to minor throat and bronchial irritation. It aids in loosening phlegm (mucus) and thinning bronchial secretions, facilitating drainage of the bronchial tubes.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The maximum recommended dosage for adults and children aged 12 years and older is 2 teaspoons (10 mL) every 4 hours, not to exceed 6 doses within a 24-hour period. This product is specifically formulated for adult use and is not intended for children under 12 years of age.

Healthcare professionals should instruct patients to measure the dosage using the dosing cup provided with the product. It is essential to keep the dosing cup with the product to ensure accurate measurement.

Contraindications

Use is contraindicated in the following situations:

• Keep out of reach of children to prevent accidental ingestion.

• Discontinue use and consult a healthcare professional if the patient experiences nervousness, dizziness, or sleeplessness.

• If symptoms do not improve within 7 days or are accompanied by fever, medical advice should be sought.

• In cases where a cough persists for more than 7 days, recurs, or is accompanied by fever, rash, or a persistent headache, these may indicate a serious condition requiring medical evaluation.

Warnings and Precautions

The use of this product is contraindicated in individuals currently taking prescription monoamine oxidase inhibitors (MAOIs), which are medications prescribed for depression, psychiatric or emotional conditions, or Parkinson's disease. Additionally, it is advised to refrain from using this product for a minimum of two weeks following the cessation of an MAOI. Healthcare professionals should counsel patients to verify with their doctor or pharmacist if they are uncertain whether their prescription medication contains an MAOI.

Patients should be instructed to discontinue use and seek medical advice if they experience symptoms such as nervousness, dizziness, or insomnia. Furthermore, if symptoms do not improve within seven days or are accompanied by fever, or if a cough persists for more than seven days, recurs, or is associated with fever, rash, or a persistent headache, patients must contact their healthcare provider. These symptoms may indicate a more serious underlying condition that requires further evaluation.

In the event of an overdose, it is critical to obtain emergency medical assistance immediately or contact a Poison Control Center for guidance. Prompt action is essential to ensure patient safety and effective management of the situation.

Side Effects

Patients should be aware of the potential adverse reactions associated with the use of this medication. Serious adverse reactions may occur, particularly in individuals who are currently taking or have recently discontinued a prescription monoamine oxidase inhibitor (MAOI). The use of this medication is contraindicated in such cases, as it may lead to significant health risks.

Common adverse reactions that warrant immediate medical attention include symptoms such as nervousness, dizziness, or sleeplessness. Patients are advised to discontinue use and consult a healthcare professional if these symptoms occur. Additionally, if symptoms do not improve within 7 days or are accompanied by fever, or if a cough persists for more than 7 days, recurs, or is associated with fever, rash, or a persistent headache, patients should seek medical advice, as these may indicate a serious underlying condition.

Before initiating treatment, it is important for patients to consult a healthcare provider if they have a history of heart disease, high blood pressure, thyroid disease, diabetes, or difficulty urinating due to an enlarged prostate gland. Furthermore, patients with a cough that produces excessive phlegm or those with chronic cough conditions, such as smoking-related cough, asthma, chronic bronchitis, or emphysema, should also seek medical guidance prior to use.

Patients taking other oral nasal decongestants or stimulants should consult a doctor or pharmacist before using this medication to avoid potential interactions.

Drug Interactions

The concomitant use of this medication with prescription monoamine oxidase inhibitors (MAOIs) is contraindicated. Patients should not take this medication while on MAOIs or for a period of two weeks following the discontinuation of MAOI therapy, as this may result in serious interactions.

Additionally, it is advisable for patients to consult with a healthcare professional, such as a doctor or pharmacist, prior to using this medication if they are currently taking any other oral nasal decongestants or stimulants. The combination may elevate the risk of adverse effects, necessitating careful monitoring or dosage adjustments as deemed appropriate by the healthcare provider.

No specific drug interactions or laboratory test interactions have been identified for this medication.

Packaging & NDC

Below are the non-prescription pack sizes of Mucosan Multi-Symptom Cherry (dextromethorphan hydrobromide, guaifenesin, and phenylephrine hydrochloride). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

This adult strength product is not intended for use in pediatric patients under 12 years of age. Children under 12 years should not use this medication.

Geriatric Use

Elderly patients may require special consideration when using this adult strength product, which is not intended for use in children under 12 years of age. Prior to use, it is advisable for geriatric patients to consult a healthcare provider if they have a history of heart disease, high blood pressure, thyroid disease, diabetes, or urinary difficulties due to an enlarged prostate gland.

Additionally, elderly patients should seek guidance from a doctor or pharmacist before using this product if they are concurrently taking any other oral nasal decongestants or stimulants. It is crucial for geriatric patients to adhere strictly to the recommended dosage and to avoid exceeding it.

Monitoring for adverse effects is particularly important in this population. Elderly patients should discontinue use and consult a healthcare provider if they experience symptoms such as nervousness, dizziness, or sleeplessness. Furthermore, if symptoms do not improve within 7 days, or if they are accompanied by fever, or if a cough persists for more than 7 days, recurs, or is associated with fever, rash, or a persistent headache, these may indicate a serious condition that requires medical evaluation.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully considered in these populations to ensure the safety of both the mother and the fetus or infant.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data on the excretion of this drug in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

There is no specific information regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

There is currently no specific information available regarding overdosage for this medication. Healthcare professionals are advised to monitor patients closely for any unusual symptoms or adverse effects that may arise. In the event of suspected overdosage, it is recommended to initiate supportive care and symptomatic treatment as necessary.

Healthcare providers should consider contacting a poison control center for guidance on management strategies tailored to the specific situation. Continuous assessment of the patient's clinical status is essential to ensure appropriate interventions are implemented promptly.

Nonclinical Toxicology

If pregnant or breast-feeding, it is advised to consult a health professional before use. No specific non-teratogenic effects have been identified. Additionally, there are no detailed findings related to nonclinical toxicology or animal pharmacology and toxicology available.

Postmarketing Experience

Postmarketing experience has identified several adverse reactions reported voluntarily or through surveillance programs in patients using Mucosan Multi-Symptom Cherry. The following reactions have been noted: nervousness, dizziness, sleeplessness, rash, and persistent headache.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion. In the event of an overdose, patients should be instructed to seek medical help or contact a Poison Control Center immediately.

Patients should be informed to discontinue use and consult a doctor if they experience symptoms such as nervousness, dizziness, or sleeplessness. Additionally, they should be advised to stop use and seek medical advice if their symptoms do not improve within 7 days or if they are accompanied by fever. It is important to inform patients that they should also stop use and consult a doctor if their cough persists for more than 7 days, returns, or is accompanied by fever, rash, or a persistent headache, as these may indicate a serious condition.

Healthcare providers should encourage patients to consult a doctor before using the medication if they have any of the following conditions: heart disease, high blood pressure, thyroid disease, diabetes, or difficulty urinating due to an enlarged prostate gland. Patients should also be advised to seek medical advice if they have a cough that produces excessive phlegm or if they have a chronic cough associated with smoking, asthma, chronic bronchitis, or emphysema.

Finally, patients should be reminded to consult a doctor or pharmacist before using this medication if they are currently taking any other oral nasal decongestant or stimulant to avoid potential interactions.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at a temperature range of 15-30°C (59-86°F). Refrigeration is not recommended, as it may compromise the integrity of the product. Proper handling and storage conditions must be adhered to in order to maintain product efficacy and safety.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Mucosan Multi-Symptom Cherry, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)